US Bancorp DE Acquires 530 Shares of argenx SE (NASDAQ:ARGX)

US Bancorp DE boosted its stake in argenx SE (NASDAQ:ARGX - Free Report) by 12.2% in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 4,880 shares of the company's stock after buying an additional 530 shares during the quarter. US Bancorp DE's holdings in argenx were worth $3,001,000 at the end of the most recent quarter.

A number of other institutional investors also recently modified their holdings of ARGX. FMR LLC grew its stake in shares of argenx by 35.9% in the 3rd quarter. FMR LLC now owns 4,793,472 shares of the company's stock valued at $2,598,445,000 after buying an additional 1,265,486 shares in the last quarter. Janus Henderson Group PLC lifted its stake in argenx by 0.4% in the third quarter. Janus Henderson Group PLC now owns 2,479,207 shares of the company's stock valued at $1,343,797,000 after acquiring an additional 10,975 shares during the last quarter. Wellington Management Group LLP grew its position in argenx by 13.0% in the third quarter. Wellington Management Group LLP now owns 482,346 shares of the company's stock worth $261,470,000 after acquiring an additional 55,617 shares in the last quarter. Alkeon Capital Management LLC increased its stake in shares of argenx by 15.0% during the 3rd quarter. Alkeon Capital Management LLC now owns 345,000 shares of the company's stock worth $187,018,000 after purchasing an additional 45,000 shares during the last quarter. Finally, Jennison Associates LLC raised its holdings in shares of argenx by 27.0% during the 4th quarter. Jennison Associates LLC now owns 302,149 shares of the company's stock valued at $185,821,000 after purchasing an additional 64,183 shares in the last quarter. Institutional investors and hedge funds own 60.32% of the company's stock.

Remove Ads

Wall Street Analysts Forecast Growth

ARGX has been the topic of several recent research reports. HC Wainwright raised their target price on argenx from $717.00 to $720.00 and gave the company a "buy" rating in a report on Friday, February 28th. Truist Financial reiterated a "buy" rating and issued a $700.00 target price (up from $660.00) on shares of argenx in a research note on Tuesday, January 14th. Guggenheim raised their price target on argenx from $775.00 to $1,100.00 and gave the company a "buy" rating in a research report on Monday. William Blair reaffirmed an "outperform" rating on shares of argenx in a report on Friday, February 28th. Finally, Evercore ISI upped their price target on argenx from $675.00 to $706.00 and gave the stock an "outperform" rating in a report on Thursday, November 21st. One research analyst has rated the stock with a sell rating, two have given a hold rating, eighteen have assigned a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, argenx currently has a consensus rating of "Moderate Buy" and a consensus price target of $687.00.

argenx Stock Performance

NASDAQ ARGX traded down $23.21 during trading on Monday, reaching $571.00. 548,019 shares of the company traded hands, compared to its average volume of 283,470. The company has a market cap of $34.69 billion, a price-to-earnings ratio of -648.86 and a beta of 0.59. argenx SE has a 1-year low of $349.86 and a 1-year high of $678.21. The stock's 50 day moving average price is $641.45 and its two-hundred day moving average price is $594.49.

argenx (NASDAQ:ARGX - Get Free Report) last released its quarterly earnings data on Thursday, February 27th. The company reported $1.58 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.98 by $0.60. argenx had a negative return on equity of 1.45% and a negative net margin of 2.11%. The firm had revenue of $761.22 million during the quarter, compared to analyst estimates of $678.52 million. Equities research analysts expect that argenx SE will post 3.13 EPS for the current fiscal year.

argenx Profile

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren's syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.